Buradasınız

Anasayfa » Content

TÜYLÜ HÜCRELİ LÖSEMİ TANILI İKİ OLGUDA BiRİNCİ DİZİ VE NÜKSTE KLADRİBİN UYGULAMASI

ADMINISTRATION OF CLADRIBINE IN HAIRY CELL LEUKEMIA AT INITIAL PRESENTATION AND AT RELAPSE: REPORT OF TWO CASES

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Hairy cell leukemia (HCL) is a rare chronic lymphoproliferative disease, which is treatable with the nucleoside analogue, cladribine (2-chlorodeoxyadenosine) both at initial presentation and at relapse. Presented herein are two cases of HCL, with CR on cladribine and relapsing on 6th and 14th years of initial diagnosis. The first patient achieved a second CR 3 months after the reinfusion of cladribine with disapperance of reticulin fibers and absence of hairy cells on bone marrow biopsy. The second patient succumbed to neutropenic fever, candida pneumonia and septic shock at the 23rd day of cladribine infusion.
Bookmark/Search this post with
Abstract (Original Language): 
Tüylü hücreli lösemi (THL) birinci dizi ve nükste purin nükleozid analoğu olan kladribin (2-klorodeoksiadenozin) ile tedavi edilebilen nadir görülen kronik seyirli lenfoproliferatif hastalıktır. Bu yazıda THL tanısı ile kladribin uygulanarak tam remisyon (TR) elde edilmiĢ ve tanının 6.yılında nüks nedeniyle tekrar kladribin uygulanması sonrası 3.ayda kemik iliği biyopsisinde retikülin liflerinin kaybolduğu, tüylü lösemi hücrelerinin de saptanmadığı (tekrar TR elde edilen) bir olgu ve THL tanısı ile kladribin uygulanarak TR elde edilen, tanının 14.yılında nüks THL tanısıyla kladribin uygulanmasının 23.gününde nötropenik ateĢ, candida pnömonisi ve septik Ģok sonucu eks olan ikinci bir olgu bildirilmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-tuylu-hucreli-losemi-tanili-iki-olguda-birinci-dizi-nukste-kladribin-uygulamasi.pdf
  • 4
66-71
  • Turkish

REFERENCES

References: 

1. Beutler E. Cladribine (2-chlorodeoxyadenosine). Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92307. Lancet. 1992;340:952-956.
2. Bouroncle, BA, Wiseman, BK, Doan, CA. Leukemic reticuloendotheliosis. Blood 1958; 13:609.
3. Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW Jr, Robins RK, Montgomery JA. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980;77:6865-6869.
4. Cohen A, Hirshhorn R, Horowitz SD, Rubinstein A, Polmar SH, Hong R, Martin DW Jr. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 ;75:472-476.
5. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 228 hairy cell leukemia patients treated with pentostatin or cladribine with 15.4 years median time from diagnosis. Blood 112:731, 2008.
6. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-740.
7. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007;110:2240-2247.
8. Flandrin G, Sigaux F, Sebahoun G, Bouffette P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol. 1984 11:458-471.
9. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2:1067-1079.
10. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-896.
11. Grever MR. How I treat hairy cell leukemia. Blood. 2010 ;115:21-28.
12. Groll AH, Walsh TJ. Invasive fungal infections in the neutropenic cancer patient. Abstr Hematol Oncol 2003; 6(1): 18-26.
13. Juliusson G, Christiansen I, Hansen MM, Johnson S, Kimby E, Elmhorn-Rosenborg A, Liliemark J. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol. 1996 Jul;14(7):2160-6.
14. Juliusson G, Heldal D, Hippe E, Hedenus M, Malm
İstanbul Tıp Fakültesi Dergisi Cilt / Volume: 74• Sayı / Number: 4 • Yıl/Year: 2011
70
13. Juliusson G, Christiansen I, Hansen MM, Johnson S, Kimby E, Elmhorn-Rosenborg A, Liliemark J. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol. 1996 ;14:2160-2166.
14. Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman K, Stolt CM, Evensen SA, Albertioni F, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol. 1995 ;13:989-995.
15. Juliusson G, Liliemark J. Purine analogues: rationale for development, mechanisms of action, and pharmacokinetics in hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20:1087–1097.
16. Labouyrie E, Marit G, Vial JP, Lacombe F, Fialon P, Bernard P, de Mascarel A, Merlio JP. Intrasinusoidal bone marrow involvement by splenic lymphoma with villous lymphocytes: a helpful immunohistologic feature. Mod Pathol. 1997;10:1015-1020.
17. Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica. 1999;84:22–25.
18. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990 ;322:1117-1121.
19. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109:3672-3675.
20. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998 ;92:1918-1926.
21. Schrek R, Donnelly WJ. "Hairy" cells in blood in lymphoreticular neoplastic disease and "flagellated" cells of normal lymph nodes. Blood. 1966 ;27:199-211.
22. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906-2911.
23. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin). J Clin Oncol. 1984;2:1336-1342.
24. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica. 2004;89:309–313.

Thank you for copying data from http://www.arastirmax.com